Tegaserod

• Irritable Bowel Syndrome with Constipation
• Functional Constipation
• Chronic Constipation

Tegaserod (Zelnorm) is a selective serotonin 5-HT4 receptor partial agonist with a narrow re-approved indication for irritable bowel syndrome with constipation (IBS-C) in women under 65 years of age who have inadequate response to other therapies. Originally approved in 2002, tegaserod was withdrawn from the U.S. market in 2007 after observational data raised concerns about cardiovascular ischemic events. It returned in 2019 with a tightly defined population, a robust risk evaluation and mitigation strategy (REMS) program, and a careful exclusion of any patient with cardiovascular risk factors. Patients should understand that the medication is intended specifically for moderate-to-severe IBS-C symptoms after non-pharmacologic measures and first-line agents have failed.

Mechanism of Action

Tegaserod selectively activates 5-HT4 receptors located on enteric nerve terminals throughout the gastrointestinal tract. As a partial agonist, it produces submaximal but durable receptor activation that triggers release of acetylcholine and calcitonin gene-related peptide from intrinsic primary afferent neurons. The downstream effect is initiation of the peristaltic reflex, with coordinated contractions proximal and relaxation distal to the bolus, accelerated colonic transit, and increased intestinal chloride and bicarbonate secretion that softens stool consistency.

Three clinically relevant outcomes follow from these actions. First, transit times in the small intestine and colon shorten measurably, reducing the symptom of infrequent and incomplete bowel movements. Second, increased luminal fluid secretion reduces stool hardness, which lessens straining and the painful component of IBS-C. Third, modulation of visceral afferent signaling appears to reduce the heightened pain perception characteristic of IBS, with patient-reported abdominal discomfort improving in clinical trials. Tegaserod's selectivity for the 5-HT4 receptor over related serotonergic targets is incomplete, which is partly why off-target cardiovascular concerns emerged at higher doses in patients with vascular disease. The NIDDK IBS resource provides a useful overview of the underlying disorder.

Clinical Use

Tegaserod's place in the IBS-C algorithm is third- or fourth-line. First-line management includes dietary modification (soluble fiber, low FODMAP trial), adequate hydration, regular physical activity, and over-the-counter osmotic laxatives such as polyethylene glycol. Second-line includes prescription secretagogues such as linaclotide and lubiprostone, which have broader approved populations and longer post-market experience. Tegaserod is considered when these options are ineffective or poorly tolerated and the patient meets the strict eligibility criteria.

Eligibility excludes any woman with a history of myocardial infarction, stroke, transient ischemic attack, angina, or unstable cardiovascular disease, as well as women age 65 or older. The American Gastroenterological Association guideline conditionally recommends tegaserod for IBS-C in eligible women, acknowledging the narrow population. Comparative effectiveness data show response rates of roughly 40 to 50 percent vs about 25 to 35 percent on placebo at 4 weeks. Patient selection requires baseline cardiovascular risk stratification, often including assessment of blood pressure, lipid profile, hemoglobin A1c, smoking status, and family history of premature coronary disease. Our gastrointestinal team can guide whether tegaserod, a secretagogue, or non-pharmacologic optimization is the best next step. The IBS vs IBD article and the stress and gut-brain article help patients distinguish these conditions and understand the mind-gut interactions that often shape symptom severity. Cognitive behavioral therapy, gut-directed hypnotherapy, and structured dietary trials such as the low FODMAP elimination and reintroduction protocol have substantial evidence in IBS and should be considered alongside or instead of pharmacotherapy in many patients. Antispasmodics, low-dose tricyclic antidepressants, and rifaximin are additional options with different evidence bases for various IBS subtypes.

How to Take It

The approved dose is 6 mg by mouth twice daily, taken approximately 30 minutes before meals — typically before breakfast and before dinner. Pre-meal administration takes advantage of the gastrocolic reflex and produces more reliable and earlier post-meal bowel activity. Swallow the tablet whole with a glass of water. If a dose is missed and the meal is upcoming within 30 minutes, take it; if more time has passed, skip and resume the normal schedule rather than stacking doses. Store at room temperature.

Most patients notice some change in stool frequency and form within the first week, with maximum benefit at 4 to 6 weeks. If there is no meaningful response by 4 to 6 weeks of consistent dosing, the medication should be discontinued because continued exposure does not improve the chance of response and only accumulates risk. A symptom diary that tracks stool frequency, Bristol Stool Scale form, abdominal pain severity, and bloating is the most reliable way to assess whether the response is meaningful enough to justify continued therapy. The first week may bring transient diarrhea, headache, abdominal cramping, or flatulence; persistent or severe diarrhea warrants immediate discontinuation and contact with the prescriber, as it may signal ischemic colitis. Hydration and continued attention to dietary fiber and physical activity remain important even on tegaserod, because the medication works best when other contributors to constipation are addressed concurrently. Slow-transit constipation, pelvic floor dysfunction, and medication-induced constipation from opioids, anticholinergics, calcium channel blockers, or iron supplements may require separate management strategies layered onto or in place of pharmacotherapy.

Monitoring and Follow-Up

Before starting tegaserod, complete a focused cardiovascular risk assessment including blood pressure, fasting lipid panel, hemoglobin A1c, and an ASCVD risk score calculation. Document the absence of contraindicated conditions and ensure the patient is enrolled in the REMS program with signed acknowledgment of risks. Symptom severity should be quantified at baseline using IBS-C symptom diaries or validated tools such as the IBS Severity Scoring System.

Follow-up at 4 weeks reviews response and side effects. Treatment beyond 4 to 6 weeks without clear benefit should be discontinued. For responders, reassessment every 3 months addresses ongoing benefit, emergence of cardiovascular risk factors, and any episodes of severe diarrhea, ischemic-pattern abdominal pain, or rectal bleeding. Blood pressure and pulse are checked at each visit. Annual reassessment of cardiovascular risk should occur because eligibility can change as patients age or develop new comorbidities. Any new cardiac event, transient ischemic attack, or stroke during therapy is an immediate indication to discontinue and not resume. The transition into the contraindicated age bracket at 65 also requires preplanned discontinuation and identification of an alternative therapy in advance.

Special Populations

Tegaserod is contraindicated in men, in women age 65 and older, in any patient with a history of cardiovascular ischemic events or active ischemic disease, in severe renal impairment with creatinine clearance below 15 mL/min or end-stage renal disease, in moderate or severe hepatic impairment (Child-Pugh class B or C), in active or prior ischemic colitis or intestinal ischemia, in suspected mechanical bowel obstruction, in symptomatic gallbladder disease or sphincter of Oddi dysfunction, in significant abdominal adhesions, and in current or prior suicidal ideation or behavior. Pregnancy data are limited but reassuring; the medication is generally avoided unless clearly needed. Lactation transfer is unknown; weigh risks individually. Pediatric use is not approved. Strong CYP enzyme interactions are minimal because tegaserod is not metabolized by CYP450 in clinically significant amounts; it modestly reduces digoxin exposure (about 15 percent) so digoxin levels should be monitored if the combination is used. The FDA Zelnorm prescribing information details the full restricted prescribing framework.

When to Contact Your Doctor

Seek emergency care for chest pain, pressure or tightness, sudden severe abdominal pain (especially with bloody or maroon-colored stools), one-sided weakness or numbness, slurred speech, sudden severe headache, fainting, or new vision loss — these may signal myocardial infarction, stroke, ischemic colitis, or intestinal ischemia and require immediate evaluation. Call promptly for persistent or severe diarrhea, signs of dehydration (dizziness, low urine output, dark urine), new rectal bleeding, persistent abdominal cramping, or new or worsening depression and any thoughts of self-harm. Any swelling of the face or tongue, hives, or trouble breathing is an allergic reaction warning sign. Stop the medication and contact the prescriber for any new cardiac event diagnosis or new cardiovascular risk factors that emerge during therapy.

If chronic constipation and IBS-C symptoms are interfering with daily life despite first-line measures, contact us or schedule a visit so our team can complete a thorough evaluation, review eligibility against the strict cardiovascular criteria, coordinate any necessary subspecialty consultation, and decide whether tegaserod, a secretagogue, or non-pharmacologic optimization is the right next step in your individualized treatment plan.